ANIK Stock - Anika Therapeutics, Inc.
Unlock GoAI Insights for ANIK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $119.91M | $120.79M | $113.83M | $147.79M | $130.46M |
| Gross Profit | $76.00M | $82.53M | $73.22M | $82.94M | $69.03M |
| Gross Margin | 63.4% | 68.3% | 64.3% | 56.1% | 52.9% |
| Operating Income | $-5,101,000 | $844,000 | $3.67M | $2.62M | $-28,322,000 |
| Net Income | $-56,385,000 | $-82,667,000 | $-14,859,000 | $4.13M | $-23,982,000 |
| Net Margin | -47.0% | -68.4% | -13.1% | 2.8% | -18.4% |
| EPS | $-3.83 | $-5.64 | $-1.02 | $0.29 | $-1.69 |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 17th 2025 | B. Riley Securities | Initiation | Buy | $21 |
| November 1st 2024 | Barrington Research | Reiterated | Outperform | $25← $37 |
| August 14th 2023 | Barrington Research | Upgrade | Outperform | $24 |
| March 7th 2023 | Barrington Research | Downgrade | Market Perform | - |
| November 9th 2022 | Barrington Research | Upgrade | Outperform | $31 |
| October 14th 2022 | Stephens | Resumed | Equal Weight | $26 |
Earnings History & Surprises
ANIKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $-0.13 | $-0.13 | 0.0% | = MET |
Q2 2025 | May 9, 2025 | $0.09 | $-0.06 | -166.7% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.01 | $-0.03 | -200.0% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $0.30 | $-0.25 | -183.3% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.23 | $0.17 | -26.1% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.19 | $-0.31 | -63.2% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-0.26 | $-4.30 | -1553.8% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.33 | $-0.45 | -36.4% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.34 | $-0.19 | +44.1% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.36 | $-0.71 | -97.2% | ✗ MISS |
Q1 2023 | Mar 6, 2023 | $-0.22 | $-0.34 | -54.5% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.24 | $-0.29 | -20.8% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-0.26 | $-0.20 | +23.1% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.31 | $-0.20 | +35.5% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $-0.25 | $-0.40 | -60.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.21 | $0.04 | +119.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.15 | $0.45 | +400.0% | ✓ BEAT |
Latest News
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $16
📈 PositiveAnika Initiates $15M 10b5-1 Share Repurchase Program Supporting Shareholder Returns And Strategic Flexibility
📈 PositiveAnika Therapeutics Q3 Adj. EPS $0.04 Beats $(0.27) Estimate, Sales $27.800M Inline
📈 PositiveBarrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target
📈 PositiveAnika slumps after trial setback for cartilage repair product
📉 NegativeFrequently Asked Questions about ANIK
What is ANIK's current stock price?
What is the analyst price target for ANIK?
What sector is Anika Therapeutics, Inc. in?
What is ANIK's market cap?
Does ANIK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ANIK for comparison